FDA Gives 510(K) Nod To Vapotherm's Next-Gen High-Velocity Therapy

by Vandana Singh, Benzinga Editor

August 30, 2021 11:29 AM | 1 min read |

The FDA has granted 510(k) clearance to Vapotherm Inc's VAPO HVT (high-velocity therapy) 2.0.
Vapotherm high-velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distress.
The next-generation system is designed to provide high-velocity therapy using an integrated air source, eliminating the need for wall air or any pressurized air source.
When paired with an oxygen source, the HVT 2.0 will support patients whether they need respiratory support in the hospital or home setting.
The company is planning a limited commercial release of HVT 2.0 in the U.S. in Q4 of 2021.
Related content: Benzinga's Full FDA Calendar.
Price Action: VAPO stock is up 4.27% at $28.57 on the last check Monday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.